Skip to main content
OpenTrials
Completed

NCT Number: NCT01438892

Impact Of RA Therapy Compliance On Patient-Reported Outcomes

Several observational studies have evaluated the comparative treatment costs associated with each agent, particularly those within the anti-TNF class, but few have evaluated the impact of therapy compliance, persistence, treatment patterns on patient reported outcomes, healthcare utilization and costs, using a provider database. This study is designed to fill in this information gap.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Cohort observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults with moderate to severe RA who are currently using a DMARD

Exclusion criteria

  • Psoriatic Arthritis (PsA), Psoriasis (PsO), SSystemic Lupus Erythematosus (SLE), Non-Disease modifying anti-rheumatic disease (non-DMARD) use

Treatment and study plan

tDMARDs

Drug

Traditional DMARDs for RA

biodmards

Drug

Biologic DMARDs

Primary outcomes

  1. HAQ

    Time frame: 12 months

  2. 36-Item Short-Form Health Survey (SF-36)

    Time frame: 12 months

Secondary outcomes

  1. Compliance

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Sep 22, 2011
Registry last updated
Apr 8, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.